Literature DB >> 11756607

Response to first drug trial predicts outcome in childhood temporal lobe epilepsy.

D J Dlugos1, M D Sammel, B L Strom, J T Farrar.   

Abstract

OBJECTIVE: To construct a clinical prediction model for the early identification of children destined to develop refractory temporal lobe epilepsy (TLE) 2 years after epilepsy onset.
METHODS: Patients with TLE between 1 and 18 years old seen in the Division of Neurology at Children's Hospital of Philadelphia during 1999 were identified through billing records and chart review. Data were abstracted independently on 5 candidate predictor variables for refractory TLE and on seizure frequency outcome at 2 years after epilepsy onset.
RESULTS: One hundred twenty patients met inclusion criteria and had at least 2 years of follow-up. Forty-five of 120 patients (37.5%) had refractory TLE at 2 years after onset, and 75 of 120 (62.5%) were seizure free. Three significant predictors of refractory TLE were found on bivariate analysis: an early risk factor for epilepsy (risk ratio = 3.5 [95% CI 2.2, 5.6]), temporal lobe abnormality on MRI scan (2.9 [95% CI 1.9, 4.6]), and failure of the first antiepileptic drug (AED) trial (16.5 [95% CI 6.3, 43.9]). Logistic regression indicated that the best model to predict refractory TLE contained only the variable "failure of first AED trial," with a positive predictive value of 0.89 (95% CI 0.76, 0.96) and negative predictive value of 0.95 (95% CI 0.87, 0.99) to predict "refractory TLE" at 2 years.
CONCLUSIONS: Failure of first AED trial accurately predicts refractory TLE at 2 years after onset, based on retrospective cohort data in children. If verified prospectively and with longer follow-up, this finding should support earlier consideration of surgical options.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11756607     DOI: 10.1212/wnl.57.12.2259

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

1.  Refractory epilepsy: one size does not fit all.

Authors:  Jacqueline A French
Journal:  Epilepsy Curr       Date:  2006 Nov-Dec       Impact factor: 7.500

Review 2.  Medical therapy of epilepsy: when to initiate treatment and when to combine?

Authors:  Martin J Brodie
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

3.  Pharmacoresistance with newer anti-epileptic drugs in mesial temporal lobe epilepsy with hippocampal sclerosis.

Authors:  Michael S Pohlen; Jingxiao Jin; Ronnie S Tobias; Atul Maheshwari
Journal:  Epilepsy Res       Date:  2017-09-19       Impact factor: 3.045

4.  A population-based study of long-term outcome of epilepsy in childhood with a focal or hemispheric lesion on neuroimaging.

Authors:  Radhika Dhamija; Brian D Moseley; Gregory D Cascino; Elaine C Wirrell
Journal:  Epilepsia       Date:  2011-07-18       Impact factor: 5.864

5.  Complete remission in nonsyndromic childhood-onset epilepsy.

Authors:  Anne T Berg; Francine M Testa; Susan R Levy
Journal:  Ann Neurol       Date:  2011-06-27       Impact factor: 10.422

Review 6.  The current treatment of epilepsy: a challenge of choices.

Authors:  Joseph I Sirven
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

7.  Frequency, prognosis and surgical treatment of structural abnormalities seen with magnetic resonance imaging in childhood epilepsy.

Authors:  Anne T Berg; Gary W Mathern; Richard A Bronen; Robert K Fulbright; Francis DiMario; Francine M Testa; Susan R Levy
Journal:  Brain       Date:  2009-07-28       Impact factor: 13.501

Review 8.  The natural history of epilepsy: an epidemiological view.

Authors:  P Kwan; J W Sander
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

Review 9.  Identification of pharmacoresistant epilepsy.

Authors:  Anne T Berg
Journal:  Neurol Clin       Date:  2009-11       Impact factor: 3.806

Review 10.  Refractory epilepsy in children.

Authors:  Satinder Aneja; Puneet Jain
Journal:  Indian J Pediatr       Date:  2014-08-09       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.